Abstract
Enoximone (Perfan – Merrell) and milrinone (Primacor – Sterling-Winthrop) are phosphodiesterase inhibitors marketed for short-term intravenous use in patients with heart failure on intensive care units. The manufacturers claim that enoximone is ‘a first-line inotrope for the failing heart’ while milrinone is advocated for ‘resistant heart failure’. Are these drugs useful additions to existing treatments?
Subject
Pharmacology (medical),General Medicine
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献